MR-39 shows favorable pharmacokinetic characteristics and displays strong anti-inflammatory activities in lipopolysaccharide (LPS)-stimulated rat primary microglial cells, reducing interleukin-1β (Il-1β) and Tumor necrosis factor-α (Tnf-α) levels; in addition, it has a good permeation rate in hCMEC/D3 cells, an in vitro model of the blood–brain barrier [57], and alleviates the inflammatory process associated with Alzheimer diseases [58]. The gene discussed is TNF; the disease is early-onset autosomal dominant Alzheimer disease.